Dyadic's Non-Animal Dairy Enzyme Achieves Milestone, Targets 2026 Commercialization
DYAI is trading near its 52-week low of $0.711 (14% above the low) on light trading volume (0.4× avg).
Summary
Dyadic Applied BioSolutions announced a significant step forward in its collaboration with Inzymes ApS, achieving a key development milestone for their recombinant non-animal bovine chymosin. This enzyme, crucial for cheese production, is now slated for commercialization in 2026. As a result of this achievement, Dyadic received a $200,000 milestone payment and is positioned to earn future royalties from sales in the estimated $1.5-$2.0 billion global dairy processing enzyme market. This progress validates Dyadic's proprietary microbial expression platforms and signals a new potential revenue stream, which is material for a company of its size. Investors will monitor the commercialization timeline and the potential for future royalty income.
At the time of this announcement, DYAI was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.71 to $1.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.